(Q53338986)

13 May 2018

title

Donepezil use in managed Medicare: effect on health care costs and utilization. (English)

1 reference

13 May 2018

author name string

Fillit H

series ordinal

1

1 reference

13 May 2018

Gutterman EM

series ordinal

2

1 reference

13 May 2018

Lewis B

series ordinal

3

1 reference

13 May 2018

publication date

1 December 1999

1 reference

13 May 2018

published in

Clinical Therapeutics

1 reference

13 May 2018

volume

21

1 reference

13 May 2018

issue

12

1 reference

13 May 2018

page(s)

2173-2185

1 reference

13 May 2018

Donepezil. Pharmacoeconomic implications of therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Chronic care costs in managed care.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Cost of Alzheimer's disease and related dementia in managed-medicare.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Alzheimer's disease under managed care: implications from Medicare utilization and expenditure patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Cognitive function and the costs of Alzheimer disease. An exploratory study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

An economic evaluation of donepezil in the treatment of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Guidelines on drug treatments for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

The US economic and social costs of Alzheimer's disease revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

The cost of institutional care in Alzheimer's disease: nursing home and hospital use in a prospective cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

The surge in Medicare managed care: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Analysis and interpretation of cost data in randomised controlled trials: review of published studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

The economic value of informal caregiving

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Alzheimer's disease care: costs and potential savings.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

The course of psychopathologic features in mild to moderate Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

The spectrum of behavioral changes in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Evaluation of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Disease, drugs, decisions, and dollars.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Estimated prevalence of Alzheimer's disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Can home care services achieve cost savings in long-term care for older people?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

The effect of accurate patient screening on the cost-effectiveness of case management programs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

Community care for demented and non-demented elderly people: a comparison study of financial burden, service use, and unmet needs in family supporters

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987246-X

7 January 2021

10.1016/S0149-2918(00)87246-X

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

10645761

1 reference

13 May 2018